Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $140.3 million.

  • Apellis Pharmaceuticals' Accumulated Expenses rose 0.35% to $140.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.3 million, marking a year-over-year increase of 0.35%. This contributed to the annual value of $140.2 million for FY2024, which is 9.68% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Accumulated Expenses of $140.3 million as of Q3 2025, which was up 0.95% from $139.0 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Accumulated Expenses' 5-year high stood at $140.3 million during Q3 2025, with a 5-year trough of $69.4 million in Q1 2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $122.8 million (2024), whereas its average is $119.4 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 312.96% in 2021, then tumbled by 33.42% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $103.2 million in 2021, then fell by 7.85% to $95.1 million in 2022, then skyrocketed by 34.34% to $127.8 million in 2023, then increased by 9.68% to $140.2 million in 2024, then rose by 0.35% to $140.3 million in 2025.
  • Its Accumulated Expenses stands at $140.3 million for Q3 2025, versus $139.0 million for Q2 2025 and $116.1 million for Q1 2025.